
ALTUS data show the multi-target HCC blood test score tracks tumor size, Milan status, and LI-RADS category rather than liver disease severity.

Binu John, MD, MPH, is an associate professor of medicine and chief of gastroenterology and hepatology at the University of Miami

ALTUS data show the multi-target HCC blood test score tracks tumor size, Milan status, and LI-RADS category rather than liver disease severity.

ALTUS findings presented at AASLD show mt-HBT detects early-stage HCC with >66% higher sensitivity than ultrasound, addressing gaps in liver cancer surveillance.